期刊
EXPERT OPINION ON DRUG DELIVERY
卷 8, 期 4, 页码 415-433出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425247.2011.559457
关键词
-
资金
- United States National Institutes of Health [1RO1 NS057748, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635, P01 MH64570, 5 P01 DA026146, 1P01 DA028555, P01 NS43985, RO1 NS051334, 2RO1 CA89225, 1 R01 CA116591, UO1 CA151806, 1P20 RR021937]
- United States Department of Defense [W81XWH-09-1-0386, DoD USAMRMC 06108004]
- Government of Russian Federation [02.740.11.523, 11.G4.31.0004]
Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood--brain or blood--tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据